BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
Your view on BCRX
Overview
What the company does, where it operates, and who runs it.
About BioCryst Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jon P. Stonehouse
- Headquarters
- 4505 Emperor Boulevard, Durham, NC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jon P. Stonehouse
- Headquarters
- 4505 Emperor Boulevard, Durham, NC, US
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for BioCryst Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. BCRX last traded at $7.61; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for BioCryst Pharmaceuticals, Inc.. Starting points for BioCryst Pharmaceuticals, Inc.: EPS -$1.41, beta 0.54 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for BioCryst Pharmaceuticals, Inc.. BioCryst Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for BioCryst Pharmaceuticals, Inc.. Trailing twelve-month EPS for BioCryst Pharmaceuticals, Inc. stands at -$1.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$19.00
average of 3 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy5
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.09 | $0.14 | -$2.29 | $0.56 |
| Low estimate | $0.03 | $0.12 | -$2.44 | $0.43 |
| High estimate | $0.15 | $0.15 | -$2.15 | $0.72 |
| No. of analysts | 3 | 2 | 4 | 5 |
| Year-ago EPS | $1.121 | -$2.981 | $1.211 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $165.80M | $166.91M | $718.43M | $739.90M |
| Low estimate | $157.38M | $161.32M | $668.75M | $679.12M |
| High estimate | $171.00M | $171.39M | $762.96M | $789.60M |
| No. of analysts | 6 | 2 | 7 | 7 |
| Year-ago revenue | $406.56M | $156.41M | $874.84M | — |
| Growth | -59.2% | +6.7% | -17.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Pulse 2.0; as of Nov 14, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for BioCryst Pharmaceuticals, Inc.. BioCryst Pharmaceuticals, Inc. has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- AVIRAtea Pharmaceuticals, Inc.Biotechnology$345M
- PHVSPharvaris N.V.Biotechnology$2.3B
- VIRVir Biotechnology, Inc.Biotechnology$1.7B
More Biotechnology companies
- PAR.AXParadigm Biopharmaceuticals LimitedASX
- PARDPoniard Pharmaceuticals, Inc.OTC$150
- PASGPassage Bio, Inc.NASDAQ$14M
- PBIGFParadigm Biopharmaceuticals LimitedOTC$88M
- PBLAPanbela Therapeutics, Inc.OTC$53,889
- PBLSParabilis Medicines, Inc.NASDAQ$3.5B
- PBMPsyence Biomedical Ltd.NASDAQ$59,815
- PBMWWPsyence Biomedical Ltd. WarrantNASDAQ$1,140
- PBYIPuma Biotechnology, Inc.NASDAQ$402M
- PCSAProcessa Pharmaceuticals, Inc.NASDAQ$5M
- PCVXVaxcyte, Inc.NASDAQ$10.0B
- PDSBPDS Biotechnology CorporationNASDAQ$49M
ETFs holding BioCryst Pharmaceuticals, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.54%
- IWMiShares Russell 2000 ETF$76.6B in assets0.06%
- VBVanguard Small-Cap ETF$76.9B in assets0.01%
- PBEInvesco Biotechnology & Genome ETF$438M in assets2.14%
- SBIOALPS Medical Breakthroughs ETF$187M in assets1.28%
- BBPVirtus LifeSci Biotech Products ETF$127M in assets1.16%
- FDLSInspire Fidelis Multi Factor ETF$255M in assets0.90%
Largest holders first, then the funds most concentrated in BCRX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold BioCryst Pharmaceuticals, Inc., and how their positions are changing. At a $1.96B market value, institutional positions materially move BioCryst Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by BioCryst Pharmaceuticals, Inc. executives and directors. Shares of BioCryst Pharmaceuticals, Inc. have traded between $6.00 and $11.31 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming BioCryst Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for BioCryst Pharmaceuticals, Inc.. Coverage tracks BioCryst Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of BioCryst Pharmaceuticals, Inc.